TVTX vs GLNG Comparison

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Golar LNG Ltd designs, converts, owns, and operates marine infrastructure for the liquefaction of natural gas and provides floating liquefied natural gas (FLNG) services. It offers solutions for gas resource holders to develop and utilize gas reserves, including stranded, associated, flared, or underutilized resources. The company's reportable segments are: i) FLNG: includes the operations of FLNG vessels and projects, and ii) Corporate and other: includes legacy shipping segment activities, vessel management, floating storage and regasification unit services for third parties. The majority of the company's revenue is derived from the FLNG segment. Geographically, it generates the maximum revenue from Cameroon.